Showing 721 - 740 results of 13,350 for search '(( a ((step decrease) OR (teer decrease)) ) OR ( i ((largest decrease) OR (larger decrease)) ))', query time: 0.69s Refine Results
  1. 721
  2. 722
  3. 723
  4. 724
  5. 725
  6. 726

    S1 Data - by Alhassan Abdul-Mumin (5986151)

    Published 2024
    “…The total number of deliveries and fresh stillbirths showed a step change with a marked decrease during the pandemic, while the macerated stillbirths showed a pulse change, a temporary marked decrease with a quick recovery over time.…”
  7. 727
  8. 728

    Superiority of ARMA model identification during stochastic pacing vs. a time domain analysis after a step change in BCL. by Mathieu Lemay (330649)

    Published 2013
    “…<p><i>A</i>: Response of the Ca<sup>2+</sup>-driven model with positive Ca<sup>2+</sup> to APD coupling to a step decrease of BCL from 400 to 390 ms. …”
  9. 729
  10. 730
  11. 731
  12. 732
  13. 733
  14. 734
  15. 735
  16. 736
  17. 737
  18. 738
  19. 739

    Image1_Biochanin A Regulates Key Steps of Inflammation Resolution in a Model of Antigen-Induced Arthritis via GPR30/PKA-Dependent Mechanism.TIF by Franciel Batista Felix (10699536)

    Published 2021
    “…BCA treatment shortened Ri from ∼23 h observed in vehicle-treated mice to ∼5.5 h, associated with an increase in apoptotic events and efferocytosis, both key steps for the resolution of inflammation. These effects of BCA were prevented by H89, an inhibitor of protein kinase A (PKA) and G15, a selective G protein–coupled receptor 30 (GPR30) antagonist. …”
  20. 740

    Image2_Biochanin A Regulates Key Steps of Inflammation Resolution in a Model of Antigen-Induced Arthritis via GPR30/PKA-Dependent Mechanism.TIF by Franciel Batista Felix (10699536)

    Published 2021
    “…BCA treatment shortened Ri from ∼23 h observed in vehicle-treated mice to ∼5.5 h, associated with an increase in apoptotic events and efferocytosis, both key steps for the resolution of inflammation. These effects of BCA were prevented by H89, an inhibitor of protein kinase A (PKA) and G15, a selective G protein–coupled receptor 30 (GPR30) antagonist. …”